Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement
Compass updated its corporate presentation to include COMPANION-002 data showing tovecimig improved ORR and PFS in 2L biliary tract cancer and plans FDA engagement ahead of a BLA.Key Highlights:Original SEC Filing: Compass Therapeutics, Inc. [ CMPX ] - 8-K - Jul. 01, 2026This is an AI-powered summa…